Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
Change company Symbol lookup
Select an option...
CYTHW Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
ATAI ATAI Life Sciences NV
FTS Fortis Inc
VLO Valero Energy Corp
BBLN+ Babylon Holdings Equity Warrants 21st Oct 2026 *W EXP 10/21/2026
NEGG Newegg Commerce Inc
LTRY Lottery.com Inc
RCLF Rosecliff Acquisition Corp I
SSYS Stratasys Ltd
GRN iPath? Series B Carbon ETN
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta-cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The Company's product lines include Trappsol and Aquaplex. It sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. Its products include Trappsol HPB and Trappsol other product. The Company also operates a fine chemical business, consisting of the sale of cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Price
Delayed
$0.37
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
0

Display:

Providers:

UpdateCancel
6 providers
September 07, 2022
Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases...(BusinessWire)

August 16, 2022
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

--- Continued execution on advancement of lead development program evaluating Trappsol(R) Cyclo(TM) for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC(TM)) Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo...(BusinessWire)

August 08, 2022
Cyclo Therapeutics to Present at the China NPC Association Meeting

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases...(BusinessWire)

July 21, 2022
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases...(BusinessWire)

July 11, 2022
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.